A 2023 analysis published in JAMA Internal Medicine (Blumenthal et al.) examined mental health outcomes in patients using GLP-1 receptor agonists and found no significant increase in adverse psychiatric events compared to control groups, offering reassurance about the general safety profile of these medications in patients managing mental health conditions
This wasn't true for any other patch on the list
The complexities arise from Section 503A of the Federal Food, Drug, and Cosmetic Act, which relates to the necessary conditions for drug compounding.20 The rules concerning the compounding of therapeutic peptides state that they must come from accredited compounding pharmacies, and the compounded drug must either be compounded from an existing FDA-approved drug product or use drug products included on the 503A bulks list (i.e., the FDAs roster of compoundable substances.)21 But many therapeutic peptides dont satisfy either of the 503A conditions
That, my dear, is called the Sunday Scaries
During the last test week, apocynin also improved the hand-eye coordination performance compared with vehicle treatment (resp
Menopause, obesity, and incretin therapy: new horizons in the fight for womens metabolic health
